Almac to Host Inaugural European Product Launch Workshop for US Biopharmaceutical Companies
CRAIGAVON, Northern Ireland, May 11, 2011 /PRNewswire/ -- Almac is hosting its inaugural European Product Launch workshop in Boston, MA on 17th May 2011. Targeted specifically at the biopharmaceutical sector, the workshop provides consultative advice and services to US companies to successfully launch drug products onto the European market.
The workshop will provide US companies with important market and regulatory framework knowledge, whilst guiding them through the European product launch process right through from submitting an MAA to final distribution of drug products to end-users.
Attendees will also learn from the real life experiences of three of Almac's many US clients who have successfully launched drug products into the European marketplace including: Eisai Inc, Millennium: The Takeda Oncology Company and The Medicines Company.
Ian Markwell, VP of Quality for Almac's Pharma Services business unit commented 'This workshop provides a significant opportunity for US companies to learn first hand of the processes of launching product into Europe, as many companies based outside the EU, find the European regulatory and quality framework complex.'
One of the key presenters at the workshop Ms Trudy Burke, Senior Director, Baltimore & Gliadel Operations, Eisai Inc remarked: 'I am delighted to share my experience of partnering with Almac, while helping to advise US companies on the challenges of launching a high value, temperature sensitive product in Europe.'
Further details of this workshop can be found at http://almaceuproductlaunch.eventbrite.com or by contacting Tania Davis (Tania.email@example.com) directly.
About Almac Group
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, pharmaceutical development, clinical trial supply and IXRS(R) technology (IVRS/IWRS), to commercial-scale manufacture and packaging. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 3,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new North American Headquarters located in Souderton PA.
For more information about the Almac Group, please visit http://www.almacgroup.com or e-mail firstname.lastname@example.org
Contact: Tania Davis Almac Pharma Services T: +44(0)28-3836-3363 E : email@example.com OR Tristan Jervis DeFacto T.Jervis@Defacto.com Tel: +44-2078-613019
SOURCE Almac Group